Image 1-Pemazyre (pemigatinib) - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Pemazyre™ (pemigatinib) for the Treatment of Cholangiocarcinoma

Image 1-Pemazyre (pemigatinib)
PemazyreTM (pemigatinib) is the first and only FDA approved FGFR inhibitor indicated for the treatment of Cholangiocarcinoma. Credit: Incyte Corporation.